Ah receptor |
CYP1A (mRNA, protein) |
[58,64] |
(in-) activation |
EROD-Assay |
ISO/TS 23893-2 |
Metal sequestration |
Metallothionein (protein) |
[59] |
Endocrine disruption |
Vitellogenin, protein |
ISO/DIS 23893-3 |
Vitellogenin, mRNA |
(under development), [65] |
CYP19/aromatase (mRNA, protein, activity) |
[66] |
Steroid levels (blood) |
[67] |
Histopathological changes in gonadal tissue |
[68] |
Thyroid hormone disruption |
Transthyretin (TTR), mRNA |
[69] |
Thyroid hormone levels |
|
Genotoxic effects |
Micronucleus test |
ISO 12427-2 |
DNA adducts |
[70] |
DNA strand breaks (Comet assay) |
[71] |
Oxidative stress |
Lipid peroxidation |
[58] |
Phase II enzymes and cofactors |
[62,72] |
Antioxidant enzymes |
|
Neurotoxicity |
Inhibition of acetylcholinesterase activity |
[73,74] |
Immunotoxicity |
Phagocytic activity |
[75] |
Macrophage aggregates |
[76] |
Other blood parameters |
[77] |
Cellular integrity |
Neutral red retention assay (lysosomal stability assay) |
[78] |
Cell/Tissue damage |
Histopathological changes |
[60] |